225 related articles for article (PubMed ID: 21998288)
1. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.
Goldstein EJ; Solomkin JS; Citron DM; Alder JD
Clin Infect Dis; 2011 Dec; 53(11):1074-80. PubMed ID: 21998288
[TBL] [Abstract][Full Text] [Related]
2. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece.
Papaparaskevas J; Pantazatou A; Katsandri A; Houhoula DP; Legakis NJ; Tsakris A; Avlamis A
J Antimicrob Chemother; 2008 Jul; 62(1):137-41. PubMed ID: 18385145
[TBL] [Abstract][Full Text] [Related]
3. Determination of moxifloxacin anaerobic susceptibility breakpoints according to the Clinical and Laboratory Standards Institute guidelines.
Ambler J; Rennie R; Poupard J; Koeth L; Stass H; Endermann R; Choudhri S
Diagn Microbiol Infect Dis; 2008 May; 61(1):49-57. PubMed ID: 18342475
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez H
Antimicrob Agents Chemother; 2006 Jan; 50(1):148-55. PubMed ID: 16377680
[TBL] [Abstract][Full Text] [Related]
5. Role of moxifloxacin for the treatment of community-acquired [corrected] complicated intra-abdominal infections in Taiwan.
Lau YJ; Chen YH; Huang CT; Lee WS; Liu CY; Liu JW; Liu HD; Lee YJ; Chen CW; Ko WC; Hsueh PR
J Microbiol Immunol Infect; 2012 Feb; 45(1):1-6. PubMed ID: 22244019
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
Edmiston CE; Krepel CJ; Kehl KS; Seabrook GR; Somberg LB; Almassi GH; Smith TL; Loehrl TA; Brown KR; Lewis BD; Towne JB
J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
[TBL] [Abstract][Full Text] [Related]
7. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study.
De Waele JJ; Tellado JM; Alder J; Reimnitz P; Jensen M; Hampel B; Arvis P
Int J Antimicrob Agents; 2013 Jan; 41(1):57-64. PubMed ID: 23153963
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.
Noel AR; Bowker KE; Macgowan AP
Antimicrob Agents Chemother; 2005 Oct; 49(10):4234-9. PubMed ID: 16189103
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Thadepalli H; Chuah SK; Gollapudi S
Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081
[TBL] [Abstract][Full Text] [Related]
10. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens.
Stein GE; Schooley S; Tyrrell KL; Citron DM; Nicolau DP; Goldstein EJ
Anaerobe; 2008 Feb; 14(1):8-12. PubMed ID: 17983770
[TBL] [Abstract][Full Text] [Related]
11. Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomised controlled trials.
Mu YP; Liu RL; Wang LQ; Deng X; Zhu N; Wei MD; Wang Y
Int J Clin Pract; 2012 Feb; 66(2):210-7. PubMed ID: 22257046
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
Malangoni MA; Song J; Herrington J; Choudhri S; Pertel P
Ann Surg; 2006 Aug; 244(2):204-11. PubMed ID: 16858182
[TBL] [Abstract][Full Text] [Related]
13. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Goldstein EJ
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S106-11. PubMed ID: 12173118
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
[TBL] [Abstract][Full Text] [Related]
16. Differences in distribution and antimicrobial susceptibility of anaerobes isolated from complicated intra-abdominal infections versus diabetic foot infections.
Claros M; Citron DM; Goldstein EJ; Merriam CV; Tyrrell KL
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):546-8. PubMed ID: 23727512
[TBL] [Abstract][Full Text] [Related]
17. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
18. Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria.
Wybo I; Piérard D; Verschraegen I; Reynders M; Vandoorslaer K; Claeys G; Delmée M; Glupczynski Y; Gordts B; Ieven M; Melin P; Struelens M; Verhaegen J; Lauwers S
J Antimicrob Chemother; 2007 Jan; 59(1):132-9. PubMed ID: 17095529
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.
Roberts SA; Shore KP; Paviour SD; Holland D; Morris AJ
J Antimicrob Chemother; 2006 May; 57(5):992-8. PubMed ID: 16507560
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.
Walkty A; Boyd DA; Gravel D; Hutchinson J; McGeer A; Moore D; Simor A; Suh K; Taylor G; Miller M; Mulvey MR;
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):419-24. PubMed ID: 20226332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]